Legend Biotech Corporation
LEGN
$18.55
-$0.55-2.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.12% | 70.28% | 38.54% | 115.04% | 142.52% |
| Total Other Revenue | 98.16% | -93.59% | -99.88% | -97.30% | -14,814.63% |
| Total Revenue | 64.21% | 69.99% | 36.74% | 107.52% | 134.80% |
| Cost of Revenue | 26.05% | 51.30% | 20.37% | 11.28% | 29.10% |
| Gross Profit | 888.75% | 376.19% | 150.64% | 135.30% | 114.07% |
| SG&A Expenses | 21.68% | 9.75% | 23.28% | 28.99% | 33.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.04% | 36.96% | 21.20% | 15.98% | 30.41% |
| Operating Income | 72.50% | 38.24% | 47.87% | 57.03% | 38.12% |
| Income Before Tax | -148.34% | 67.68% | -594.48% | -65.80% | 127.62% |
| Income Tax Expenses | -21.20% | -86.11% | 157.52% | 35,620.00% | 813.84% |
| Earnings from Continuing Operations | -217.12% | 68.33% | -589.05% | -68.78% | 118.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -217.12% | 68.33% | -589.05% | -68.78% | 118.17% |
| EBIT | 72.50% | 38.24% | 47.87% | 57.03% | 38.12% |
| EBITDA | 75.18% | 40.00% | 49.78% | 57.76% | 39.00% |
| EPS Basic | -216.24% | 68.56% | -583.63% | -67.18% | 118.02% |
| Normalized Basic EPS | -145.43% | 67.90% | -588.78% | -61.38% | 130.38% |
| EPS Diluted | -225.92% | 67.83% | -580.90% | -67.18% | 117.99% |
| Normalized Diluted EPS | -149.89% | 67.90% | -588.78% | -61.38% | 127.67% |
| Average Basic Shares Outstanding | 0.77% | 0.74% | 0.84% | 0.97% | 0.82% |
| Average Diluted Shares Outstanding | -8.28% | 0.74% | 0.84% | 0.97% | 10.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |